Jie Wu

机构：Xidian University, Changzhi Medical College, Ministry of Agriculture, University of Oklahoma Health Sciences Center · ORCID：0000-0002-2864-1606

发表论文 186 篇 · 总被引 10364 次 · h-index 52

代表论文

• Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations (2020 · Annals of Oncology · 被引 257)
• Precision therapy for RET-altered cancers with RET inhibitors (2021 · Trends in cancer · 被引 178)
• The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib (2021 · npj Precision Oncology · 被引 51)
• RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectives (2023 · Pharmacology & Therapeutics · 被引 48)
• Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer (2021 · Annals of Oncology · 被引 45)
• Whole brain radiotherapy (WBRT) for leptomeningeal metastasis from NSCLC in the era of targeted therapy: a retrospective study (2020 · Radiation Oncology · 被引 43)